1. J Med Biochem. 2019 Mar 1;38(1):38-44. doi: 10.2478/jomb-2018-0013.
eCollection  2019 Mar.

Novel Mutations in Serbian MEN1 Patients: Genotype-phenotype Correlation.

Isailovic T(1), Milicevic I(2), Macut D(1), Petakov M(1), Ognjanovic S(1), 
Popovic B(1), Antic IB(1), Bogavac T(2), Kovacevic VE(2), Ilic D(2), Damjanovic 
S(1).

Author information:
(1)Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of 
Serbia, School of Medicine, University of Belgrade, Belgrade, Serbia.
(2)Clinic for Endocrinology, Diabetes and Metabolic Diseases, Clinical Center of 
Serbia, Belgrade, Serbia.

BACKGROUND: Multiple endocrine neoplasia type 1 (MEN1) is an autosomal dominant 
cancer syndrome characterized by the occurrence of primary hyperparathyroidism 
(PHPT), pituitary adenoma (PA) and pancreatic neuroendocrine tumor (pNET). 
Whether the underlying mutations in MEN1 gene predict clinical presentation of 
affected heterozygotes or not, is still a matter of a debate.
METHODS: Clinical and genetic analysis of 90 consecutive MEN1 patients was 
performed in a retrospective, single - center study.
RESULTS: MEN1 mutation was found in 67 (74.4%) patients belonging to 31 
different families. Twenty nine different heteozygous mutations were found, 
including 6 novel point mutations (W220G, 941delG, 1088del7, 1184insA, 
1473del10, 1602del17) and one large deletion of exon 8. Truncating mutations 
predicted development of pNETs (OR=5.8, 95% CI 1.7 - 19.7%) and PHPT (OR=4.3, 
95% CI 1.5 - 12.4%).
CONCLUSIONS: Large number of novel mutations among MEN1 patients confirmed 
previously reported data. PNETs and PHPT were more frequent in patients with 
truncating mutations.

Publisher: UVOD: Multipla endokrina neoplazija tip 1 (MEN1) predstavlja 
autozomalno dominantni kancerski sindrom koji se karakte riše pojavom primarnog 
hiperparatireoidizma (PHPT), tumora hipofize i pankreasnih neuroendokrinih 
tumora (pNET). U kojoj meri postojanje heterozigotne mutacije u MEN1 genu 
određuje kliničku sliku nosilaca i dalje predstavlja predmet diskusije.
METODE: U okviru retrospektivne studije jednog centra, spro vedeno je kliničko i 
gensko ispitivanje 90 uzastopnih pacijenata sa MEN1 sindromom.
REZULTATI: Mutacija u MEN1 genu nađena je kod 67 (74,4%) pacijenata koji su 
pripadali 31 različitoj porodici. Identifikovano je dvadeset devet različitih 
heterozigotnih mutacija, uključujući i 6 novootkrivenih (W220G, 941delG, 
1088del7, 1184insA, 1473del10, 1602del17) i jednu veli ku deleciju 8. egzona. 
Mutacije koje dovode do skraćenja proteina predvidele su pojavu pNET (OR=5,8, 
95% CI 1,7 – 19,7%) i PHPT (OR=4,3, 95% CI 1,5 – 12,4%).
ZAKLJUČAK: Veliki broj novootkrivenih mutacija među MEN1 pacijentima je u skladu 
sa prethodno objavljenim podacima. Pankreasni NET i PHPT su bili značajno češći 
kod pacijenata sa mutacijama koje dovode do skraćenja proteina.

DOI: 10.2478/jomb-2018-0013
PMCID: PMC6298455
PMID: 30820182

Conflict of interest statement: Conflict of interest statement The author stated 
that she has no conflicts of interest regarding the publication of this article.